Robert Preti

Robert Preti has a long and varied work experience. Since 2012, they have been a Chairman, Member of the Board and Executive Committee, and Vice Chairman of the Alliance for Regenerative Medicine. In 2015, they became a Director and Chief Technology Officer & SVP Development and Manufacturing at Caladrius Biosciences. In 2020, they were the General Manager, Chief Strategy Officer, Life Science Business Headquarters at Hitachi Chemical Corporation, and Chief Strategy Officer, Minaris Life Sciences at Minaris Regenerative Medicine. In 2021, they were a Strategic Advisor at Ori Biotech. In 2022, they became an Independent Director at RoosterBio Inc., a Managing Director at Current Biologics (a JV by CTI Clinical Trials and Cincinnati Children's Hospital Medical Center), and a Principal at Robert A Preti Advisory, LLC. Robert has also been a Member of the Board of Directors at AABB since 2007.

Robert Preti obtained a Bachelor of Science (BS) in Biology, General from Fordham University between 1975 and 1978. Robert then went on to earn a PhD in Hematology, Cell Biology, and Metabolism from New York University between 1982 and 1987.